– UK, Oxford – Circassia Pharmaceuticals plc (LSE: CIR), a specialty biopharmaceutical company focused on allergy and asthma, today announces the appointment of Marvin S Samson as a Non-Executive Director. Circassia also announces that Paul R Edick has informed the Company he will retire from the Board at its meeting on 17 May 2016, and therefore will not seek re-election as a Non-Executive Director at the Company’s 2016 Annual General Meeting.
Dr Francesco Granata, Circassia’s Chairman, commented: “We are delighted to welcome Marvin to Circassia. With his impressive track record founding and growing successful specialty pharmaceutical companies, his experience and expertise will be hugely valuable as we rapidly expand our commercial presence and bring our exciting allergy and asthma products to market. We also wish to thank Paul for his highly valuable contribution and strategic guidance during his time on the Board. His contribution has been particularly welcome during the recent transformative period for the Company, and we look forward to his continued input over the coming months.”
Marvin S Samson brings to Circassia 50 years’ experience of the specialty pharmaceutical industry, having established and led a number of successful companies. He is currently Founder and CEO of Samson Medical Technologies LLC, and was until recently Interim President of the University of the Sciences, Philadelphia. Previously, he was CEO and Chairman of Qualitest Pharmaceuticals, Group Vice President of Injectables at Teva, CEO and President of SICOR, Founder, President and CEO of Marsam Pharmaceuticals and Founder, CEO and President of Elkins-Sinn. He holds a BSc in Chemistry from Temple University, Philadelphia.
He is currently a Non-Executive Director of Antares Pharma Inc, Flynn Pharma Ltd and NanoPass Technologies Ltd. He is also Chairman of the Board of Trustees of the University of the Sciences in Philadelphia and a Board Member of the Cooper Rowan Medical School, Virtua Health and the Franklin Institute.
About Circassia
Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings by the end of H1 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
